A company was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to treat patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). MMAE is a potent anti-cancer drug that is a CYP3A substrate and a weak competitive CYP3A inhibitor
了解更多关于 Phoenix Hosted
Phoenix Hosted 作为基于云的解决方案,使研究团队能够依托 Phoenix 平台的行业金标准软件,管理从非房室分析(NCA)到群体建模的全流程。

联系我们